🚀 VC round data is live in beta, check it out!
Probi Valuation Multiples
Discover revenue and EBITDA valuation multiples for Probi and similar public comparables like Aura Biosciences, Neurogene, Recbio, Avacta Group and more.
Probi Overview
About Probi
Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. Its research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).
Founded
1991
HQ
Employees
165
Website
Sectors
Financials (FY)
EV
$338M
Probi Financials
Probi reported last fiscal year revenue of $66M and EBITDA of $12M.
In the same fiscal year, Probi generated $23M in gross profit, $12M in EBITDA, and $2M in net income.
Revenue (LTM)
Probi P&L
In the most recent fiscal year, Probi reported revenue of $66M and EBITDA of $12M.
Probi expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $66M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $23M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBITDA | — | XXX | $12M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 2% | XXX | XXX | XXX |
| Net Profit | — | XXX | $2M | XXX | XXX | XXX |
| Net Margin | — | XXX | 3% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Probi Stock Performance
Probi has current market cap of $362M, and enterprise value of $338M.
Market Cap Evolution
Probi's stock price is $31.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $338M | $362M | 0.0% | XXX | XXX | XXX | $0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProbi Valuation Multiples
Probi trades at 5.1x EV/Revenue multiple, and 27.7x EV/EBITDA.
EV / Revenue (LTM)
Probi Financial Valuation Multiples
As of March 29, 2026, Probi has market cap of $362M and EV of $338M.
Equity research analysts estimate Probi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Probi has a P/E ratio of 203.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $362M | XXX | $362M | XXX | XXX | XXX |
| EV (current) | $338M | XXX | $338M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 27.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 282.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 14.5x | XXX | XXX | XXX |
| P/E | — | XXX | 203.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 101.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Probi Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Probi Margins & Growth Rates
Probi's revenue in the last fiscal year grew by —.
Probi Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | 18% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Probi Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aura Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Neurogene | XXX | XXX | XXX | XXX | XXX | XXX |
| Recbio | XXX | XXX | XXX | XXX | XXX | XXX |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Medigen Vaccine Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Probi M&A Activity
Probi acquired XXX companies to date.
Last acquisition by Probi was on XXXXXXXX, XXXXX. Probi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Probi
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProbi Investment Activity
Probi invested in XXX companies to date.
Probi made its latest investment on XXXXXXXX, XXXXX. Probi invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Probi
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Probi
| When was Probi founded? | Probi was founded in 1991. |
| Where is Probi headquartered? | Probi is headquartered in Sweden. |
| How many employees does Probi have? | As of today, Probi has over 165 employees. |
| Is Probi publicly listed? | Yes, Probi is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Probi? | Probi trades under PBBIF ticker. |
| When did Probi go public? | Probi went public in 2016. |
| Who are competitors of Probi? | Probi main competitors are Aura Biosciences, Neurogene, Recbio, Avacta Group. |
| What is the current market cap of Probi? | Probi's current market cap is $362M. |
| What is the current revenue of Probi? | Probi's last fiscal year revenue is $66M. |
| What is the current EV/Revenue multiple of Probi? | Current revenue multiple of Probi is 5.1x. |
| Is Probi profitable? | No, Probi is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.